Hepatic steatosis and severe fibrosis may increase risk of mortality in diabetes patients
In individuals with type 2 diabetes, hepatic steatosis and severe fibrosis were strongly linked to chances of overall and cause-specific death, says an article published in Cardiovascular Diabetology Journal.
Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes frequently coexist. Up to 75% of type 2 diabetes mellitus patients are thought to have NAFLD, which is more than twice the rate of the general population. Due to their shared metabolic risk factors, type 2 diabetes mellitus and NAFLD not only coexist but also may interact to cause related adverse outcomes.
But further research is needed to fully understand how NAFLD affects mortality in Asian people with type 2 diabetes. So, using a population-based, national Korean cohort, Goh Eun Chung and colleagues set out to evaluate the relationship between the fatty liver index (FLI) and BARD score and overall and cause-specific mortality in individuals with type 2 diabetes mellitus.
Researchers used a database from the National Health Insurance Service that was connected to death certificate data to include patients who had undergone general health examinations between 2009 and 2012 in this study. Fatty liver index (FLI) 60 was used to define hepatic steatosis, and the BARD score was used to determine advanced hepatic fibrosis.
The key findings of this study were as:
222,242 people passed away over the 8.1-year follow-up period, dying at a mortality rate of 14.3/1000 person-years.
An FLI 60 was substantially linked to an increased risk of mortality from all causes and cause-specific causes, such as cancer, liver disease, and cardiovascular disease (CVD). An FLI 60 and fibrosis (BARD 2) were associated with higher chances of death from all causes, CVDs, cancers, and liver diseases.
In conclusion, the chances of overall and cause-specific mortality in individuals with type 2 diabetes mellitus were significantly increased by hepatic steatosis and/or severe fibrosis, as determined by the FLI and BARD scores.
Reference:
Chung, G. E., Jeong, S.-M., Cho, E. J., Yoon, J. W., Yoo, J.-J., Cho, Y., Lee, K., Shin, D. W., Kim, Y. J., Yoon, J.-H., Han, K., & Yu, S. J. (2022). The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study. In Cardiovascular Diabetology (Vol. 21, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1186/s12933-022-01691-6
Next Story
